Inactive Instrument

Press Releases Brainstorm Cell Therapeutics Inc OTC Bulletin Board

Equities

US10501E1029

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 17	Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024	CI
Apr. 17	Brainstorm Cell Therapeutics Inc. Announces Management Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule	Apr. 11	PR
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment for Phase 3b Trial in ALS	Apr. 10	AQ
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS	Apr. 10	PR
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS	Apr. 09	PR
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program	Apr. 08	PR
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update	Apr. 01	PR
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference	Feb. 28	AQ
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference	Feb. 27	PR
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS	Feb. 26	AQ
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS	Feb. 23	PR
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum	Feb. 13	PR
Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline	Jan. 02	PR
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm	Dec. 31	BU
BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLI	Dec. 30	PR
BRAINSTORM CELL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm	Dec. 29	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI	Dec. 28	PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)	Dec. 28	BU
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options	Dec. 28	PR
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit	Dec. 27	PR
Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline	Dec. 27	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Brainstorm Cell Therapeutics Inc OTC Bulletin Board

Equities

US10501E1029

Press Releases

Filters